We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Alpharma Inc. (ALO.N: Quote, Profile, Research) on Monday said it would sell its generic drugs business to Iceland-based Actavis Group HF (ACT.IC: Quote, Profile, Research) for $810 million in cash, in a deal that has already been approved by the boards of both companies.
A delegation of leading US drugmakers -- which has been in negotiations with Pakistani officials for a number of weeks -- has announced a basic agreement on investment in the country's drug sector.
Recent studies confirm that the UK is the second-largest generics
market in the European Union (EU) after Germany, in both value terms and by generic penetration.
According to official data, drug consumption at China's hospitals
reached a record CNY22.2bn (US$2.72bn) in 2005, an increase of 30% over the previous year.
The European Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a positive opinion recommending marketing authorization for IONSYS(TM) (Fentanyl hydrochloride (HCl) Iontophoretic Transdermal System (ITS) 40 micrograms per dose) in the 25 member states of the European Union.
Pfizer and Sanofi-Aventis have received a positive opinion from an advisory committee to the European Medicines Agency recommending approval of their inhalable insulin product, Exubera, for the treatment of diabetes.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA -- News) announced today that trial examiners in the Japanese Patent Office have granted judgment in favor of Teva with regard to Sankyo's Patent No. 3463875 in Japan.
The Agency's scientific committee, the Committee for Medicinal Products for Human Use (CHMP), concluded, at its meeting of 10-13 October 2005, that, on the basis of the data reviewed, there are no new safety concerns regarding cardiovascular and gastrointestinal safety and serious skin reactions with non-selective NSAIDs (non-steroidal anti-inflammatory drugs).
Pharmaceutical marketers may think that the integration of regulatory policiesamong European Union countries will facilitate the switch of prescription drugs to over-the-counter status.